Baris Ungun, MD PhD

Staff Machine Learning & Optimization Engineer at TheraPanacea

Baris Ungun, MD PhD, has held various roles in the field of machine learning and engineering. Baris is currently working as a Staff Machine Learning & Optimization Engineer at TheraPanacea since October 2022. From October 2019 to August 2022, they served as a Senior Machine Learning Engineer at insitro. Prior to that, they worked at Gilead Sciences as a Formulation and Process Development Engineer from July 2008 to July 2010. Baris started their career as an intern in Fluidics Engineering at BD in 2007.

Baris Ungun, MD PhD has an extensive education history. Baris began their academic journey in 2004 and completed their undergraduate studies at Princeton University, where they earned a Bachelor of Science in Chemical Engineering in 2008. Following this, they joined Stanford University School of Medicine in 2010, where they pursued their medical degree and successfully earned a Doctor of Medicine (MD) in 2019.

During their time at Stanford University, Ungun also demonstrated a keen interest in research, specifically in the field of bioengineering. In 2012, they enrolled in the Department of Bioengineering at Stanford University for their doctoral studies. After several years of intensive research and scholarly work, they obtained their Doctor of Philosophy (PhD) in Bioengineering in 2019 from Stanford University.

Overall, Baris Ungun, MD PhD possesses a strong academic background, combining the knowledge and skills acquired in various fields such as chemical engineering, medicine, and bioengineering from prestigious institutions such as Princeton University and Stanford University.

Location

Paris, France

Links

Previous companies


Org chart

No direct reports

Teams


Offices


TheraPanacea

TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare. A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year. TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.


Industries

Headquarters

Paris, France

Employees

51-200

Links